New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2013
11:18 EDTCTIC, NTE, EXEL, IMOS, NIHDHigh option volume stocks: NIHD EXEL CTIC IMOS NTE
News For NIHD;EXEL;CTIC;IMOS;NTE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
15:57 EDTNIHDNII Holdings to explore options for Brazilian unit, Reuters reports
Subscribe for More Information
15:25 EDTNIHDNII Holdings to explore alternatives for Brazil unit, Reuters reports
06:05 EDTIMOSChipMOS reports Septemeber revenue down 16% to $48.6M
Subscribe for More Information
October 6, 2015
09:22 EDTEXELOn The Fly: Pre-market Movers
UP AFTER EARNINGS: PepsiCo (PEP), up 2.6%. ALSO HIGHER: PMC-Sierra (PMCS), up 33.8% after being acquired by Skyworks (SWKS)... Skyworks is up 2.5%... MagneGas (MNGA), up 8.9% after receiving order from a U.S. Army contractor... Exelixis (EXEL), up 5.9% after the phase 3 pivotal trial of cobimetinib met its secondary endpoint... DuPont (DD), up 6.1% after CEO and chair Ellen Kullman retires... Mallinckrodt (MNK), up 3% after providing fiscal 2016 guidance and a business update in a conference call. LOWER: EXACT Sciences (EXAS), down 34.7% after Cologuard included as an alternative screen test under the U.S. Preventive Services Task Force draft guidelines... Illumina (ILMN), down 17.7% after providing third quarter, fourth quarter, and fiscal 2015 guidance... Tesla (TSLA), down 2.5% after Model X forecasts were lowered at Morgan Stanley and the firm cut its price target to $450.
06:24 EDTNIHDNII Holdings initiated with an Underperform at Jefferies
Subscribe for More Information
05:22 EDTEXELExelixis reports phase 3 pivotal trial of cobimetinib met secondary endpoint
Subscribe for More Information
October 2, 2015
17:19 EDTCTICBiotechnology Value Fund reports 5.2% passive stake in CTI BioPharma
October 1, 2015
05:31 EDTCTICCTI BioPharma, Fred Hutchinson Cancer Research Center report research fellowship
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use